Literature DB >> 9804706

New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues.

R R Sicinski1, J M Prahl, C M Smith, H F DeLuca.   

Abstract

New highly active isomers of the natural hormone 1alpha, 25-dihydroxyvitamin D3 possessing an exomethylene group at the 2-position were prepared in a convergent manner, starting with (-)-quinic acid and the corresponding (20R)- and (20S)-25-hydroxy Grundmann ketones. These 2-methylene-19-norvitamins were efficiently converted to the 2-methyl and 2-hydroxymethyl derivatives, some of which exhibited pronounced in vivo biological activity. Configurations of the A-ring substituents were determined by 1H NOE difference spectroscopy as well as by spin decoupling experiments. It was established that the bulky methyl and hydroxymethyl substituents at C-2, due to their large conformational free energies, occupy mainly equatorial positions. Additionally, hydroxylation of the C(10)-C(19) double bond in 1alpha,25-(OH)2D3 was performed, resulting in 1alpha,19,25-trihydroxy-10,19-dihydrovitamin D3 derivatives in which the hydroxymethyl substituent at C-10, for steric reasons, is forced to occupy an axial position. In consequence, the vitamin D3 analogues were synthesized in which the 1alpha-hydroxy group, required for biological activity, is almost exclusively axially or equatorially oriented because of stabilization of the single A-ring chair conformations. The relative ability of the synthesized analogues to bind the porcine intestinal vitamin D receptor was assessed and compared with that of the natural hormone. It was established that vitamins possessing the axial orientation of the 1alpha-hydroxy substituent exhibit a significantly increased receptor binding affinity. Compounds with a 2-methylene substituent showed selective calcemic activity profiles, being extremely effective on bone calcium mobilization. 2alpha-Methyl-substituted vitamins proved to be much more active in vivo than the corresponding epimers with 2beta-configuration. All of the 2-substituted vitamins exhibited pronounced HL-60 differentiating activity, those 2alpha-substituted in the 20S-series being especially potent. The present studies imply that the axial orientation of the 1alpha-hydroxy group is necessary for biological activity of vitamin D compounds.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804706     DOI: 10.1021/jm9802618

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation.

Authors:  Nirupama K Shevde; Lori A Plum; Margaret Clagett-Dame; Hironori Yamamoto; J Wesley Pike; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

2.  Synthesis and biological activities of vitamin D-like inhibitors of CYP24 hydroxylase.

Authors:  Grazia Chiellini; Simona Rapposelli; Jinge Zhu; Ilaria Massarelli; Marilena Saraceno; Anna Maria Bianucci; Lori A Plum; Margaret Clagett-Dame; Hector F DeLuca
Journal:  Steroids       Date:  2011-11-25       Impact factor: 2.668

3.  2α-Methyl-19-nor-(20S)-1,25-dihydroxyvitamin D(3) protects the insulin 2 knockout non-obese diabetic mouse from developing type 1 diabetes without hypercalcaemia.

Authors:  C M Kiekhaefer; B Weber; M Huggins; C Gorichanaz; J A Nehring; H F DeLuca
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

4.  1α,25-Dihydroxyvitamin D(3) and its analog, 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD), suppress intraocular pressure in non-human primates.

Authors:  Galina D Kutuzova; B'ann T Gabelt; Julie A Kiland; Elizabeth A Hennes-Beann; Paul L Kaufman; Hector F DeLuca
Journal:  Arch Biochem Biophys       Date:  2011-12-16       Impact factor: 4.013

5.  20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells.

Authors:  Andrzej T Slominski; Tae-Kang Kim; Zorica Janjetovic; Robert C Tuckey; Radoslaw Bieniek; Junming Yue; Wei Li; Jianjun Chen; Minh N Nguyen; Edith K Y Tang; Duane Miller; Tai C Chen; Michael Holick
Journal:  Am J Physiol Cell Physiol       Date:  2010-12-15       Impact factor: 4.249

Review 6.  The development of a bone- and parathyroid-specific analog of vitamin D: 2-methylene-19-Nor-(20S)-1α,25-dihydroxyvitamin D3.

Authors:  Hector F Deluca
Journal:  Bonekey Rep       Date:  2014-03-05

7.  Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity.

Authors:  Andrzej T Slominski; Zorica Janjetovic; Brian E Fuller; Michal A Zmijewski; Robert C Tuckey; Minh N Nguyen; Trevor Sweatman; Wei Li; Jordan Zjawiony; Duane Miller; Tai C Chen; Gerard Lozanski; Michael F Holick
Journal:  PLoS One       Date:  2010-03-26       Impact factor: 3.240

8.  Biologically active noncalcemic analogs of 1alpha,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl.

Authors:  Lori A Plum; Jean M Prahl; Xiaohong Ma; Rafal R Sicinski; Sumithra Gowlugari; Margaret Clagett-Dame; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

9.  26- and 27-Methyl groups of 2-substituted, 19-nor-1α,25-dihydroxylated vitamin D compounds are essential for calcium mobilization in vivo.

Authors:  Pawel Grzywacz; Lori A Plum; Margaret Clagett-Dame; Hector F DeLuca
Journal:  Bioorg Chem       Date:  2013-02-09       Impact factor: 5.275

10.  2MD, a new anabolic agent for osteoporosis treatment.

Authors:  L A Plum; L A Fitzpatrick; X Ma; N C Binkley; J B Zella; M Clagett-Dame; H F DeLuca
Journal:  Osteoporos Int       Date:  2006-02-21       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.